gross profit bridgeinconsistent2023-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$742.90M
Fiscal year ended 2025-12-31Operating income
$100.10M
Fiscal year ended 2025-12-31Free cash flow
$156.80M
Fiscal year ended 2025-12-31Emergent BioSolutions Inc. (EBS) reported revenue of $742.90M and net income of $52.60M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Emergent BioSolutions Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $742.90M | $1.04B | $1.05B | $1.12B | $1.77B | $1.58B | $1.11B | $782.40M | $560.90M | $488.80M |
| Cost of revenue | $326.20M | $681.30M | Unavailable | Unavailable | Unavailable | Unavailable | $433.50M | $322.30M | $187.70M | $126.30M |
| Gross profit | $416.70M | $362.30M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $460.10M | $373.20M | $362.50M |
| Operating income | $100.10M | -$108.70M | -$726.40M | -$170.00M | $341.40M | $438.50M | $114.10M | $89.80M | $124.30M | $105.50M |
| Net income | $52.60M | -$190.60M | -$760.50M | -$211.60M | $219.50M | $305.80M | $54.50M | $62.70M | $82.60M | $51.80M |
| Research & development | $53.20M | $70.70M | $111.40M | $188.30M | $235.20M | $237.90M | $226.20M | $142.80M | $97.40M | $106.90M |
| Weighted-average diluted shares | shares 56.70M | shares 53.00M | shares 51.20M | shares 50.10M | shares 54.10M | shares 53.80M | shares 52.40M | shares 51.40M | shares 50.30M | shares 49.30M |
| Pretax income | $82.80M | -$142.90M | -$731.20M | -$219.00M | $303.20M | $411.90M | $77.40M | $81.50M | $118.60M | $99.20M |
| Income tax expense | $30.20M | $47.70M | $29.30M | -$7.40M | $83.70M | $106.10M | $22.90M | $18.80M | $36.00M | $36.70M |
| Diluted EPS | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 | $5.68 | $1.04 | $1.22 | $1.71 | $1.13 |
| Selling, general & administrative | $186.10M | $308.00M | $368.40M | $339.50M | $348.70M | $304.10M | $273.50M | $202.50M | $142.90M | $143.10M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $205.40M | $99.50M | $111.70M | $642.60M | $576.10M | $621.30M | $167.80M | $112.20M | $178.30M | $271.50M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B | $2.88B | $2.33B | $2.23B | $1.07B | $970.11M |
| Current assets | $662.50M | $598.70M | $679.50M | $1.21B | $1.27B | $1.20B | $686.20M | $620.80M | $485.40M | $510.22M |
| Total liabilities | $796.00M | $906.90M | $1.17B | $1.78B | $1.35B | $1.44B | $1.24B | $1.22B | $157.90M | $373.91M |
| Current liabilities | $132.20M | $162.40M | $651.30M | $1.23B | $374.00M | $384.50M | $216.30M | $200.40M | $100.10M | $105.86M |
| Total equity incl. NCI | $522.60M | $482.80M | $649.30M | $1.39B | $1.61B | $1.45B | $1.09B | $1.01B | $912.30M | $596.20M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $343.40M | $311.70M | $328.90M | $350.70M | $344.50M | $307.00M | $222.50M | $205.80M | $142.80M | $74.00M |
| Accounts receivable | $84.20M | $154.50M | $191.00M | $159.20M | $278.90M | $230.90M | $270.70M | $262.50M | $143.70M | $138.48M |
| Goodwill | $0 | $0 | $0 | $218.20M | $224.90M | $266.70M | $266.60M | $259.70M | $49.10M | $41.00M |
| Long-term debt | $572.10M | $663.70M | $446.50M | $448.50M | $809.40M | $841.00M | $798.40M | $784.50M | $13.50M | $248.09M |
| Accounts payable | $55.60M | $60.90M | $112.20M | $103.50M | $128.90M | $136.10M | $94.80M | $80.70M | $41.80M | $34.65M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $170.60M | $58.70M | -$206.30M | -$34.10M | $320.20M | $536.90M | $188.00M | $41.80M | $208.10M | $54.60M |
| Capital expenditures | $13.80M | $22.90M | $51.60M | $115.80M | $224.10M | $141.90M | $86.90M | $72.10M | $54.80M | $76.20M |
| Investing cash flow | $69.40M | $125.20M | $212.30M | -$381.30M | -$224.10M | -$151.90M | -$96.90M | -$897.20M | -$249.90M | -$76.20M |
| Financing cash flow | -$136.60M | -$190.00M | -$535.70M | $481.20M | -$141.00M | $69.50M | -$35.90M | $788.70M | -$51.40M | -$19.80M |
| Net change in cash | $103.50M | -$6.10M | -$530.90M | $66.30M | -$45.20M | $453.50M | $55.60M | -$66.90M | -$93.20M | -$41.30M |
| Stock-based compensation | $16.20M | $18.00M | $23.10M | $45.10M | $42.40M | $51.80M | $26.70M | $23.20M | $15.20M | $18.50M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $24.90M | $0 | $0 | $82.10M | $106.00M | $0 | $0 | $100.00K | $33.10M | $0 |
| Depreciation & amortization | $95.80M | $108.80M | $125.10M | $143.30M | $123.80M | $50.10M | $49.50M | $36.30M | $32.20M | $28.02M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $156.80M | $35.80M | -$257.90M | -$149.90M | $96.10M | $395.00M | $101.10M | -$30.30M | $153.30M | -$21.60M |
| Gross margin | 56.1% | 34.7% | Unavailable | Unavailable | 50.3% | 58.7% | Unavailable | 58.8% | 66.5% | 74.2% |
| Operating margin | 13.5% | -10.4% | -69.2% | -15.2% | 19.2% | 27.8% | 10.3% | 11.5% | 22.2% | 21.6% |
| FCF margin | 21.1% | 3.4% | -24.6% | -13.4% | 5.4% | 25.0% | 9.1% | -3.9% | 27.3% | -4.4% |
| SBC / revenue | 2.2% | 1.7% | 2.2% | 4.0% | 2.4% | 3.3% | 2.4% | 3.0% | 2.7% | 3.8% |
| Current ratio | 5.01x | 3.69x | 1.04x | 0.98x | 3.40x | 3.11x | 3.17x | 3.10x | 4.85x | 4.82x |
| Revenue YoY growth | -28.8% | -0.5% | -6.1% | -37.0% | 12.4% | 42.6% | 41.4% | 39.5% | 14.8% | Unavailable |
| Net margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | 19.4% | 4.9% | 8.0% | 14.7% | 10.6% |
| R&D / revenue | 7.2% | 6.8% | 10.6% | 16.9% | 13.3% | 15.1% | 20.5% | 18.3% | 17.4% | 21.9% |
| CapEx / revenue | 1.9% | 2.2% | 4.9% | 10.4% | 12.6% | 9.0% | 7.9% | 9.2% | 9.8% | 15.6% |
| Long-term debt / equity | 1.09x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 36.5% | Unavailable | Unavailable | Unavailable | 27.6% | 25.8% | 29.6% | 23.1% | 30.4% | 37.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EBS in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Reconciliation checks needing review
7 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
gross profit bridgeinconsistent2022-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2021-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2020-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2019-12-31
Withheld: gross profit could not be reconciled with the rest of this filer’s statement.
balance equationreview2020-12-31
Difference 3900000 exceeds tolerance 2883200.000. Presentation or filing-vintage differences need review.
balance equationreview2019-12-31
Difference 2800000 exceeds tolerance 2327300.000. Presentation or filing-vintage differences need review.